Discover binding pathways using the sliding binding-box docking approach: application to binding pathways of oseltamivir to avian influenza H5N1 neuraminidase

被引:8
|
作者
Tran, Diem-Trang T. [1 ]
Le, Ly T. [1 ,2 ]
Truong, Thanh N. [1 ,3 ]
机构
[1] Inst Computat Sci & Technol, Ho Chi Minh City, Vietnam
[2] Int Univ, Sch Biotechnol, Ho Chi Minh City, Vietnam
[3] Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA
关键词
Influenza; H5N1; Neuraminidase; Docking; Oseltamivir; Binding pathway; MOLECULAR-DYNAMICS SIMULATION; DRUG DESIGN; CONFORMATIONAL TRANSITIONS; ENSEMBLE; RESISTANCE; COMPLEX; SITES; N1;
D O I
10.1007/s10822-013-9675-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Drug binding and unbinding are transient processes which are hardly observed by experiment and difficult to analyze by computational techniques. In this paper, we employed a cost-effective method called "pathway docking" in which molecular docking was used to screen ligand-receptor binding free energy surface to reveal possible paths of ligand approaching protein binding pocket. A case study was applied on oseltamivir, the key drug against influenza a virus. The equilibrium pathways identified by this method are found to be similar to those identified in prior studies using highly expensive computational approaches.
引用
收藏
页码:689 / 695
页数:7
相关论文
共 50 条
  • [41] Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses
    Singh, Ashona
    Soliman, Mahmoud E.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4137 - 4154
  • [42] Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors
    Reina, J.
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2008, 21 (01) : 32 - 36
  • [43] The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
    Rupert J. Russell
    Lesley F. Haire
    David J. Stevens
    Patrick J. Collins
    Yi Pu Lin
    G. Michael Blackburn
    Alan J. Hay
    Steven J. Gamblin
    John J. Skehel
    Nature, 2006, 443 : 45 - 49
  • [44] The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
    Russell, Rupert J.
    Haire, Lesley F.
    Stevens, David J.
    Collins, Patrick J.
    Lin, Yi Pu
    Blackburn, G. Michael
    Hay, Alan J.
    Gamblin, Steven J.
    Skehel, John J.
    NATURE, 2006, 443 (7107) : 45 - 49
  • [45] Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes
    Hurt, A. C.
    Selleck, P.
    Komadina, N.
    Shaw, R.
    Brown, L.
    Barr, I. G.
    ANTIVIRAL RESEARCH, 2007, 73 (03) : 228 - 231
  • [46] Highly Pathogenic H5N1 Avian Influenza: Entry Pathways into North America via Bird Migration
    Peterson, A. Townsend
    Benz, Brett W.
    Papes, Monica
    PLOS ONE, 2007, 2 (02):
  • [47] Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation
    Malaisree, Maturos
    Rungrotmongkol, Thanyada
    Nunthaboot, Nadtanet
    Aruksakunwong, Ornjira
    Intharathep, Pathumwadee
    Decha, Panita
    Sompornpisut, Pornthep
    Hannongbua, Supot
    AMINO ACIDS, 2009, 37 (04) : 725 - 732
  • [48] Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach
    Karthick, Vasudevan
    Ramanathan, Karuppasamy
    SPRINGERPLUS, 2013, 2
  • [49] Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation
    Maturos Malaisree
    Thanyada Rungrotmongkol
    Nadtanet Nunthaboot
    Ornjira Aruksakunwong
    Pathumwadee Intharathep
    Panita Decha
    Pornthep Sompornpisut
    Supot Hannongbua
    Amino Acids, 2009, 37 : 725 - 732
  • [50] Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza Pharmacokinetic and Pharmacodynamic Characteristics
    Widmer, Nicolas
    Meylan, Pascal
    Ivanyuk, Anton
    Aouri, Manel
    Decosterd, Laurent A.
    Buclin, Thierry
    CLINICAL PHARMACOKINETICS, 2010, 49 (11) : 741 - 765